At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 400 target
Drug / intervention
ELUCIDATEother
Likely dose
Not stated in record
Key inclusion· 4
- ✓Histologically confirmed hepatocellular carcinoma
- ✓Histologically confirmed intrahepatic cholangiocarcinoma
- ✓Completed standard diagnostic and staging procedures per local guidelines
- ✓At least one pre-treatment blood-derived sample available
Key exclusion· 4
- ✕Unable to provide informed consent
- ✕Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma
- ✕Primary liver cancer other than HCC or iCCA
- ✕Secondary liver cancer
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
In Brief
An observational study evaluating ELUCIDATE for Hepatocellular Carcinoma and 6 related conditions. Currently recruiting, targeting 400 participants across 5 sites in 2 countries.
Signals
Enrolling ahead of pace
Detailed Summary
It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer, Primary Liver Carcinoma, Hepatic Cancer, Hepatic Carcinoma
CountriesJapan, United States
Collaborators--
Timeline
N/ARecruitingOverdue
20252026
Enrollment StartMar 2024
First PostedApr 2024
Primary CompletionJun 2026
TodayJul 2026
First PostedApr 2, 2024
Enrollment StartMar 15, 2024
Primary CompletionJun 18, 2026
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 2.2 years ago
Interventions
ELUCIDATEother
ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)